Hamburg, Germany – October 29, 2026 — During the 33rd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Byongen Therapeutics presented new preclinical data on its central ner...

BOSTON, Mass., May 14, 2026 — Byongen Therapeutics (“Byongen”), a biotechnology company specializing in next-generation AAV vector engineering, today presented non-human primate (NHP) validation data ...

BEIJING, April 30, 2026 — Byongen Therapeutics, an innovative biotechnology company dedicated to next-generation viral vector engineering, today announced that it has been selected to present one oral...

NEW ORLEANS, LA – Byongen Therapeutics, a biotechnology company specializing in next-generation viral vector engineering, today announced that it will present the latest breakthroughs from its prop...

BEIJING, February 19, 2025 — Beijing Byongen Therapeutics Co., Ltd. (Byongen Therapeutics) and Beijing Genecradle Therapeutics Technology Co., Ltd. (Genecradle Therapeutics) today announced...